Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
AssigneeBesins Healthcare Luxembourg Sarl
InventorsPhilippe Rouanet, Dominique Salin Drouin, Jacques Wepierre
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation.
Claims20
A method of treating breast cancer, comprising percutaneously administering 4-hydroxy tamoxifen to a patient having breast cancer, wherein said 4-hydroxy tamoxifen is administered in a vehicle containing isopropyl myristate as a penetration enhancer, wherein the isopropyl myristate constitutes from about 0.5% to about 2.0% by weight of the composition, at a dose of 4-hydroxy tamoxifen of at least 0.5 mg/breast per day.
Dependencies are inferred from the claim text.